Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Ms. C Thomas, a connected person:
- Date of Exercise: August 28, 2009
- Shares Exercised: 4,421 Ordinary shares under the Annual Incentive Plan
- Shares Sold: 1,806 shares
- Sale Date: September 1, 2009
- Sale Price: £12.17 per share
- Purpose: To meet tax liability arising from the exercise
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Ms. C Thomas post-transaction.
- Confirm the tax rate applied to the sale of 1,806 shares at £12.17.
- Check for any other pending director or connected person transactions not yet filed.